Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
4D Molecular Therapeutics, Inc. (FDMT) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights • Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for patients with wet age-related macular degeneration • Completed target enrollment of 50 patients in the randomized Phase 2 Dose Expansion stage of the PRISM clinical trial in July, nearly two quarters ahead of initially projected enrollment completion • Presented positive interim data from aerosolized 4D-710 Phase 1/2 AEROW clinical trial for patients with cystic fibrosis lung disease • Anticipate multiple clinical data and regulatory interaction updates onlead clinical-stage product candidates 4D-150 in wet AMD and 4D-710 in cystic fibrosis lung disease over the next 12 mo..."
05/25/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/10/2023 8-K Quarterly results
Docs: "4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights • Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for wet age-related macular degeneration at the 2023 ARVO Annual Meeting • On track for completion of enrollment of the Phase 2 Dose Expansion Stage of the PRISM clinical trial in Q3 2023 • Acquired all worldwide rights to short-form human complement factor H from Aevitas Therapeutics, Inc. and announced sCFH as payload for 4D-175 lead product candidate for geographic atrophy • Multiple additional clinical data updates on clinical-stage product candidates expected later in 2023, including on 4D-710 for cystic fibrosis lung disease in Q2 2023 • Closed upsized public offer..."
05/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, among 4D Molecular Therapeutics, Inc. and Goldman Sachs & Co. LLC, BofA Securities, Inc. and Evercore Group, L.L.C",
"Opinion of Latham & Watkins LLP"
03/15/2023 8-K Quarterly results
Docs: "4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights • Provided updates on clinical pipeline, including 4D-150 for wet age-related macular degeneration and diabetic macular edema , 4D-710 for cystic fibrosis lung disease, and 4D-310 for Fabry disease cardiomyopathy • Demonstrated robust clinical gene delivery, tolerability and initial biological activity with first three customized and evolved vectors generated from Therapeutic Vector Evolution platform • Expanded preclinical pipeline with large market geographic atrophy and alpha-1 antitrypsin deficiency lung disease programs • On track for multiple clinical data updates on lead clinical-stage product candidates during 2023 • Cash, cash equivalents and marketable ..."
01/26/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
11/09/2022 8-K Quarterly results
09/27/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/11/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
05/27/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/28/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "4D Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights — Provided clinical data updates on three programs, including first clinical data on 4D-310 for Fabry disease and 4D-125 and 4D-110 for inherited retinal dystrophies, each demonstrating preliminary evidence of clinical activity — Advanced two additional programs into clinical development: R100 vector-based 4D-150 for wet AMD, and A101 vector-based 4D-710 for cystic fibrosis — Initiated expansion of our GMP manufacturing facilities for potential commercial-scale clinical manufacturing capabilities — $315 million in cash, cash equivalents and investments at end of 2021 expected to fund operations into the second half of 2024"
02/22/2022 8-K Quarterly results
01/11/2022 8-K Investor presentation
Docs: "Corporate Presentation of 4D Molecular Therapeutics, Inc."
11/10/2021 8-K Quarterly results
Docs: "4D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and Provides Operational Highlights"
10/26/2021 8-K Other Events  Interactive Data
10/13/2021 8-K Other Events  Interactive Data
09/24/2021 8-K Quarterly results
08/12/2021 8-K Quarterly results
06/25/2021 8-K Quarterly results
05/20/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
03/25/2021 8-K Quarterly results
12/15/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 15, 2020 4D MOLECULAR THERAPEUTICS, INC. Delaware 001-39782 47-3506994 5858 Horton Street #455 Emeryville, California 94608 Registrant's telephone number, including area code: 505-2680 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-...",
"Amended and Restated Certificate of Incorporation of 4D Molecular Therapeutics, Inc",
"Amended and Restated Bylaws of 4D Molecular Therapeutics, Inc"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy